Korean Botox Explained: Products, Units and How Korea Uses Toxin

"Korean botox" means two different things depending on who is searching. For some it means a toxin made in Korea. For others it means the way Korean clinics use toxin: lighter, more often in the skin, and very often in the lower face and jaw. Both are worth explaining properly, because the first is mostly a regulatory question and the second is a clinical one.

I will keep this physician-to-physician. No product recommendations, no shopping advice. Just what I would want a colleague to know before they treat.

The Korean toxin landscape

Korea has several domestic manufacturers of botulinum toxin type A, and in Korean clinics domestic products sit alongside the imported brands you already know. Some have reached the US market under different names after their own FDA review. Each product needs its own review.

Two examples of Korean-manufactured toxins with US FDA approval for specific cosmetic indications are:

• prabotulinumtoxinA-xvfs — made by Daewoong (sold in Korea as Nabota), marketed in the US as Jeuveau. Initially FDA-approved in 2019 for temporary improvement of moderate to severe glabellar lines in adults.
• letibotulinumtoxinA-wlbg — made by Hugel (sold in Korea as Botulax), marketed in the US as Letybo. Initially FDA-approved in 2024 for temporary improvement of moderate to severe glabellar lines in adults.

US approval must be checked for each exact product and its US brand. Availability in Korea does not establish FDA approval.

Two practical points follow. First, an approval covers a specific product, manufacturer and indication, not a country of origin. "Korean" says nothing about whether a vial in your hand is approved where you practise. Second, if you practise in the US, use toxins through approved channels only. The Korean name of a product and its US name are not the same regulatory object.

Units do not convert between products

This is the point I most want readers to take away. Toxin potency units are specific to each product. A unit of one brand is not a unit of another, and the shared "U" on two labels does not make them interchangeable. Our Toxin Fact Sheet repeats this on every dilution table for a reason. In my own teaching video you see two vials on screen, a Korean product in Busan and a Korean-origin product under its US name in New York. Same "U" on both labels, different products, and the first instruction always comes from the label of the one in your hand.

The arithmetic of dilution is the same for every product: concentration is vial units divided by total volume, and units per site are concentration times aliquot. Our author reference is a 100 U vial in 2.5 mL of saline, which gives 4 U per 0.1 mL. But a dose number in any guide, including ours, only means something for the product it was written for. Switching brands means going back to that brand's label, not converting by ratio. Even vial size changes the arithmetic: a 200 U vial does not follow a 100 U table, so you redo the two lines of arithmetic for that vial.

One more trap: insulin-syringe markings are not toxin units. Read volume in millilitres and calculate from the actual concentration.

How I approach toxin in Korean practice

The products are only half the story. In my practice, the starting point is the change a patient wants. In my Korean practice, patients often describe two goals: softening upper-face lines while keeping a natural, expressive face, and refining the contour of the lower face. Concerns about a heavy brow or an awkward, stiff expression are part of that conversation. These goals guide an individual assessment and treatment plan; they do not mean every patient needs the same combination of lower-face injections.

It starts from what toxin cannot do. It cannot strengthen a muscle; it can only weaken selected ones. So there are three reasons to use it: to soften lines caused by contraction, to change expression by quieting specific muscles, and to reduce muscle bulk through disuse. My co-author Dr. Thomas B.C. Kim calls this chemical myomodulation. The aim is balance between the muscles that lift and the muscles that pull down, not a list of injection points. Smooth the forehead without that thought and you can flatten the natural arch of the brow.

Lighter doses, read from the muscle

In my practice, I start conservatively and reassess the response. In our Toxin Fact Sheet, the forehead is treated in zones rather than fixed points, at least 2 to 3 cm above the brow, and there is a zigzag pattern for a light or first treatment that sits below the standard dose range. For crow's feet, there is no fixed regional total at all: the dose per point follows the strength of the muscle you see when the patient smiles. The order matters: assess with movement, then mark. Our faculty mark points only after watching the patient frown, scrunch the nose and smile.

Near the eye, technique carries the safety. For the glabella I orient the bevel up and outward, away from the orbit, and press gently with a finger of the other hand just below the upper orbital rim as a barrier while I inject.

Toxin in the skin

The second difference is that toxin is often placed in the dermis, not only in muscle, as part of skin quality treatment. That is "skin botox", and I have written a separate article on what the evidence supports and how to keep the units knowable. Briefly: intradermal is the only defensible route, it is off-label in the US, and toxin should be injected separately from boosters rather than mixed.

The jaw and lower face

The third is how much of Korean toxin work happens below the cheekbone: the masseter, the mouth corners, the chin and the gummy smile.

Masseter reduction is the best-known example. Our Fact Sheet gives a dose range of 40–80 U in total for both sides, with about 50 U described as typical in its reference protocol. This is the bilateral total, not a per-side dose. Toxin units are product-specific, so these numbers must not be transferred directly to another formulation or treated as a universal prescription. The technique described in the Fact Sheet uses about five evenly spread intramuscular points in the most prominent part of the muscle, below the line from earlobe to mouth corner. The key safety margin is to stay roughly 1 to 1.5 cm behind the anterior border of the masseter so you do not reach the risorius and change the smile.

Two things to warn about. If the toxin does not spread evenly through the muscle, the untreated part can bulge paradoxically and needs a top-up. And in patients prone to it, masseter treatment can make the lateral cheek look hollow, so target the lower part of the muscle and tell the patient beforehand.

The same caution runs through the rest of the lower face. Toxin placed too high for the mouth corners can reach the depressor labii inferioris and make the lower lip asymmetric. Toxin that drifts above the labiomental crease from the chin can weaken the lower lip. In a gummy smile, too much dose can drop the upper lip. Even the nose needs restraint: a patient who snarls when she smiles is often using the levator labii superioris alaeque nasi, and if she relies on it to lift the upper lip, treating it for bunny lines can make the lip droop. The lower face rewards small doses and precise placement.

Before and after the injection

Whatever the product, the screen is the same. Neuromuscular disease such as myasthenia gravis, Lambert-Eaton syndrome or ALS rules toxin out, and I check for infection or inflammation at the site, known hypersensitivity, pregnancy or breastfeeding, anticoagulation or a bleeding disorder, and unrealistic expectations.

Afterwards, about four hours upright without pressing or massaging the area, though the evidence that posture alone prevents diffusion is limited. About a day without exercise, alcohol or heat. Never stop a prescribed anticoagulant without the prescriber. I follow up at about two weeks. New eyelid droop warrants prompt contact with the treating clinician; new double vision or generalised weakness needs immediate medical assessment. Difficulty swallowing, speaking or breathing requires emergency care without waiting for the routine review.

What to take from this

If you are choosing a product, the question is not "Korean or not". It is whether that specific product is approved where you practise, and whether you are dosing it by its own label. If you are learning technique, the Korean contribution is less about any vial and more about a habit: read the muscle, start light, think in zones, and treat the lower face as carefully as the upper.

Frequently asked questions

This article is educational material for medical professionals. It does not replace product labelling, local regulation or clinical judgement. Product names are mentioned for identification only; OLA Korea does not sell botulinum toxin.